Biogen Idec inks $30M genetic R&D alliance with Columbia University

Biogen Idec ($BIIB) and Columbia University Medical Center have struck a $30 million genetics R&D alliance. Some of the cash will go toward creating a sequencing and analysis center at Columbia to support collaborative research. Biogen hopes to generate qualified targets for new therapeutics by investigating the genomes of people who respond unusually to treatment. Release

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.